Specialty pharmaceuticals for hyperlipidemia - Impact on insurance premiums

New England Journal of Medicine

Volumn 373, Issue 17, 2015, Pages 1591-1593

  Schulman, Kevin A ^a,b   Balu, Suresh ^b   Reed, Shelby D ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; MORBIDITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; DRUG COST; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HYPERLIPIDEMIAS; INSURANCE; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; HUMANS; HYPERLIPIDEMIAS; INSURANCE; INSURANCE, HEALTH; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84944931298     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1509863     Document Type: Review

References (5)

1. Food and Drug Administration. Praluent (alirocumab): prescribing information. (http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/125559Orig1s000lbl.pdf.).
2. Kuklina EV, Carroll MD, Shaw KM, Hirsch R. Trends in high LDL cholesterol, cholesterollowering medication use, and dietary saturated- fat intake: United States, 1976-2010. NCHS Data Brief Number 117, March 2013 (http://www.cdc.gov/nchs/data/databriefs/db117.htm).
3. Hirsch BR, Balu S, Schulman KA. The impact of specialty pharmaceuticals as drivers of health care costs. Health Aff (Millwood) 2014;33:1714-20.
4. Lotvin AM, Shrank WH, Singh SC, Falit BP, Brennan TA. Specialty medications: Traditional and novel tools can address rising spending on these costly drugs. Health Aff (Millwood) 2014;33:1736-44.
5. Valverde AM, Reed SD, Schulman KA. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases. Health Aff (Millwood) 2012;31:2528-35.